Amberwin Pulmo, Promomed Rus’s new drug, has been registered by the Ministry of Health of the Russian Federation. It prevents the formation of cytokines in the lungs and their entry into the bloodstream, including those that provoke a severe complication of coronavirus infection called cytokine storm.
The information can be found in the State Register of Medicines. In accordance with the instructions, the medicine is prescribed for the moderate and severe course of the disease as part of complex therapy. It can be used in the form of injections and inhalations. The drug is not allowed for children and adolescents (under 18 years of age), pregnant women, as well as during breastfeeding.
Amberwin Pulmo is available as a lyophilizate for the preparation of a solution in two dosages, 1.16 mg and 5.8 mg. The manufacturer is AO Biokhimik.
According to the State Register of Clinical Trials, phase 1 trials of the drug were completed in September 2021. At the end of the year, it is planned to complete the third one.
